| Literature DB >> 34956856 |
Quanquan Gu1, Yajing Huang2, Hao Zhang3, Biao Jiang1.
Abstract
BACKGROUND: Diffuse midline glioma with H3K27-altered (DMG-H3K27a) is a novel tumor entity of the pediatric-type diffuse high-grade tumor in the latest WHO CNS 5. It mostly affects children and is only rarely found in adults. The tumor has a high level of aggressiveness, with a rapid progression and bad prognosis. In adults, the spinal cord is the most common site of DMG-H3K27a. Rare adult cases of primary DMG-H3K27a in the spinal cord were reported in this study, together with clinico-histopathologico-radiographic data.Entities:
Keywords: CNS neoplasm; diffuse midline glioma (DMG); pediatric-type gliomas; radiology; spinal cord
Year: 2021 PMID: 34956856 PMCID: PMC8694136 DOI: 10.3389/fonc.2021.701113
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Clinical information.
| No | Age/Sex | Chief complaint | PE | Preoperative diagnosis | Post-surgery PFS (month) |
|---|---|---|---|---|---|
| 1 | 49/M | Paroxysmal waist soreness for 3 months | LEMS (L/R) grade 2/3, hypesthesia in the right limb below-the-knee, numbness in the bottom of left foot | Schwannoma | 4 |
| 2 | 39/F | Back pain for 11 days, numbness in both lower limbs, and urination defecation difficulties for 1+ week | numbness below the nipple- level | Astrocytoma | 12 |
| 3 | 32/F | Numbness in left limbs for 1+ months | LEMS grade 5- (L), numbness and hypesthesia below T 2 level | Ependymoma/ Schwannoma | 7.5 |
| 4 | 65/M | Paroxysmal and progressive weakness and numbness in the right lower limb, particularly at night | Negative | Astrocytoma | 9 |
| 5 | 27/F | Numbness in both toes for 2+ months and back pain for 10+ days, relieving when side lying | Negative | Ependymoma | 20 |
LEMS, lower-limb muscle strength; PFS, Progression free survival.
Immunohistochemical findings.
| No | Age/Sex | WHO grade | ATRX | GFAP | Syn | H3K27M | H3K27Me3 | Nestin | OLIG2 | P53 | Ki-67 | Other features |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 49/M | 4 | Retain | + | + | + | Partly loss | + | + | – | 30%+ | Sparse fibers and myxoid change |
| 2 | 39/F | 4 | Retain | + | + | + | Partly loss | + | + | – | 15%+ | – |
| 3 | 32/F | 4 | Retain | + | NA | + | – | + | + | scantly + | 20%+ | Necrosis |
| 4 | 65/M | 4 | Retain | + | focally + | + | Partly loss | + | + | – | 5%+ | Necrosis |
| 5 | 27/F | 4 | Retain | + | + | + | NA | + | + | scantly + | 5%+ | Necrosis |
NA, not applicable.
"-" means negative expression; and "+" means positive expression.
Figure 1Pathological and radiographical manifestations of the Case 4 patient. Left: Results of HE and immunohistochemical staining of the tumor tissues. Right: MRI images of the tumor that was located at the T12-L1 level. The tumor exhibited heterogenous iso-hyperintense with speckled hyperintense spots inside on T2WI (A) and patchy and cystic with nodules enhancement (B–D) on contrast-enhanced MR images.
MRI presentations.
| No | Anatomical location | TumorBoundary | Necrosis and cysts | Rim of low T2 signal intensity | Marrow edema | T1WI | T2WI | Enhancement pattern* |
|---|---|---|---|---|---|---|---|---|
| 1 | T10-12 | Clear | + | – | – | Isointense | Iso- or hyperintense | Patchy |
| 2 | T1-2 | Clear | + | – | + | Hypo- or isointense | Iso- or hyperintense | Ring-like and cystic with nodules |
| 3 | C1-2 | Clear | + | + | + | Isointense | Hyperintense, with spinal cord swelling and the enlarged central canal | Patchy, ring-like and cystic with nodules |
| 4 | T12-L1 | Obscure | – | – | + | Iso- or hyperintense | Heterogeneous iso- or hyperintense, with speckled hyperintense spots inside | Patchy and cystic with nodules |
| 5 | T4-6 | Clear | + | – | + | heterogeneous hypointense | heterogeneous hyperintense, with spinal cord swelling and enlarged central canal | Patchy |
*Enhancement pattern: patchy, homogeneous, and cystic with nodules in appearance (9).
"-" means negative expression; and "+" means positive expression.